Response by disease site
. | N . | OR n (%) . | CR n (%) . | PR n (%) . | SD n (%) . | PD n (%) . |
|---|---|---|---|---|---|---|
| Blood | 7 | 6 (86) | 6 (86) | 0 (0) | 1 (14) | 0 (0) |
| Lymph nodes | 11 | 6 (55) | 6 (55) | 0 (0) | 3 (27) | 2 (18) |
| Skin | 22 | 12 (55) | 7 (31) | 5 (23) | 5 (23) | 5 (23) |
| Erythroderma | 16* | 11 (69) | 6 (38) | 5 (31) | 4 (25) | 1 (6) |
| Plaque/tumors | 10* | 4 (40) | 3 (30) | 1 (10) | 1 (10) | 5 (50) |
. | N . | OR n (%) . | CR n (%) . | PR n (%) . | SD n (%) . | PD n (%) . |
|---|---|---|---|---|---|---|
| Blood | 7 | 6 (86) | 6 (86) | 0 (0) | 1 (14) | 0 (0) |
| Lymph nodes | 11 | 6 (55) | 6 (55) | 0 (0) | 3 (27) | 2 (18) |
| Skin | 22 | 12 (55) | 7 (31) | 5 (23) | 5 (23) | 5 (23) |
| Erythroderma | 16* | 11 (69) | 6 (38) | 5 (31) | 4 (25) | 1 (6) |
| Plaque/tumors | 10* | 4 (40) | 3 (30) | 1 (10) | 1 (10) | 5 (50) |
N indicates total number of patients assessed (denominator for percentage).
Some patients had erythroderma and plaque/tumors simultaneously.